SHARE

Matinas BioPharma Holdings Inc (OTCMKTS:MTNB) a clinical-stage biopharmaceutical firm reported that it will be participating in the BIO International Convention being held from June 15 to June 18, 2015, in Philadelphia, PA. The President and CEO, Roelof Rongen will present on June 18, 2015 at the Pennsylvania Convention Center. During the presentation, the CEO of Matinas will highlight the clinical development plan for MAT2203, which is a unique formulation of Amphotericin B for the cure of invasive fungal infections, and MAT2501 which is an early-stage program to cure gram-negative bacterial infections.

The BIO International Convention

It is a significant opportunity for Matinas BioPharma to attend the Bio International Convention as it considered as one of the most influential and world’s largest biotech meetings. It is believed to attract as many as 15,000 most influential Pharma and biotech players from 65 nations, offering significant business partnering, education and networking that go far beyond professional growth.

The buzz

Recently, Matinas reported data from a head-to-head trial comparing its Phase III ready MAT9001 to Amarin Corporation plc (ADR)(NASDAQ:AMRN)’s Vascepa®. The primary objective of the ‘42’ patient trial was to compare the pharmacodynamic and pharmacokinetic effects of the two drugs, and look at key secondary objectives in cholesterol and triglyceride lessening and biomarkers of cardiovascular disease.

Release of data

The complete data will be released in a poster form in the coming period, but the top-line findings of the study demonstrate that Matinas’ drug is superior to Vascepa®, with respect to triglyceride reduction and bioavailability. It marks a significant achievement for the company as it can extend its reach in a growing industry.

In the current trading session, the stock price of MTNB declined 0.86% to close the trading session at $1.15. The decline came at a share volume of 25,700 compared to average share volume of 75,027. The market cap stands at $63.16 million.

LEAVE A REPLY